• Mashup Score: 9

    Semaglutide was associated with improved HF symptoms and exercise capacity and reduced body weight and inflammation among patients with obesity across the range of HF with mildly reduced and preserved ejection fraction, a speaker reported.The results of a secondary analysis of the STEP-HFpEF trial of semaglutide (Wegovy, Novo Nordisk) in patients with obesity and HFpEF were presented at the Heart

    Tweet Tweets with this article
    • #Semaglutide improved HF symptoms and exercise capacity and reduced body weight and inflammation in patients with #obesity across the range of #HFpEF @HFSA #HFSA2023 @ACCinTouch @JavedButler1 @bswhealth @UMMCnews #Cardiotwitter Read more 👇 https://t.co/kBvZ4UqcNX